Key result
Higher plasma adiponectin is linked to ~18% lower risk of LVH progression in hemodialysis patients.
Why the study?
Is plasma adiponectin concentration associated with changes in left ventricular mass index in maintenance hemodialysis patients?
Cohort (n=40)
No
Is plasma adiponectin concentration associated with changes in left ventricular mass index in maintenance hemodialysis patients?
Odds Ratio: 0.815 (95% CI 0.669–0.993)
p-value: p=0.042
Higher plasma adiponectin concentrations are associated with the regression of left ventricular hypertrophy in maintenance hemodialysis patients.
May inform LVH risk stratification in hemodialysis; hypothesis-generating, requires prospective trials before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2006) conducted a cohort in Hemodialysis (n=40). Plasma adiponectin concentration vs. Lower plasma adiponectin concentration was evaluated on Progression of left ventricular hypertrophy (LVH) (OR 0.815, 95% CI 0.669-0.993, p=0.042). Higher plasma adiponectin concentrations were significantly associated with a reduced risk of left ventricular hypertrophy progression over two years in hemodialysis patients (OR 0.815).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: